



# Market Announcement

5 November 2018

---

## MGC Pharmaceuticals Ltd (ASX: MXC) – Suspension from Official Quotation

### Description

The securities of MGC Pharmaceuticals Ltd ('MXC') will be suspended from quotation immediately under Listing Rule 17.2, at the request of MXC, pending the release of an announcement regarding a disposal.

### Issued by

**Ben Secrett**

Principal Adviser, Listings Compliance (Perth)

5 November 2018

Australian Securities Exchange  
Level 40, Central Park  
152-158 St Georges Tce  
Perth WA 6000

Via email: [tradinghaltspert@asx.com.au](mailto:tradinghaltspert@asx.com.au)

Dear Sir/Madam

**MGC Pharmaceuticals Ltd – Voluntary Suspension Request**

Pursuant to ASX Listing Rule 17.2, MGC Pharmaceuticals Ltd (ASX: MXC) (the “Company”) requests a voluntary suspension over the Company’s securities from the commencement of trade on Monday, 5 November 2018.

In accordance with ASX Listing Rule 17.2 the Company provides the following information regarding the request:

1. The voluntary suspension request by the Company is to allow completion of all formal documentation by CannaGlobal relating to the acquisition of MGC Derma, and simultaneous completion of related CannaGlobal transactions. The execution versions of the MGC Derma definitive agreement and supply agreement are currently being completed by CannaGlobal.
2. The Company expects the voluntary suspension to end no later than the commencement of trade on Wednesday 7 November 2018, when it anticipates it will be in a position to make an announcement to the market in respect of the abovementioned matter.
3. The Company is not aware of any reason why the voluntary suspension should not be granted, nor of any other information necessary to inform the market about the voluntary suspension.

On behalf of the Board

*[signed electronically without signature]*

Kate Sainty

**Joint Company Secretary**

**MGC Pharmaceuticals Ltd**